Next Article in Journal / Special Issue
An Overview of Bortezomib-Induced Neurotoxicity
Previous Article in Journal
Modelling Short-Term Maximum Individual Exposure from Airborne Hazardous Releases in Urban Environments. Part ΙI: Validation of a Deterministic Model with Wind Tunnel Experimental Data
Previous Article in Special Issue
Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System
Article Menu

Export Article

Open AccessReview
Toxics 2015, 3(3), 268-293;

Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies

Unitat Funcional d'Otorrinolaringologia i Al·lèrgia, Institut Universtiari Quirón Dexeus, 08028 Barcelona, Catalonia, Spain
Departament de Ciències Fisiològiques II, Universitat de Barcelona, 08907 L'Hospitalet de Llobregat, Catalonia, Spain
Servei d'Otorrinolaringologia, Hospital Universitario de Bellvitge, 08907 L'Hospitalet de Llobregat, Catalonia, Spain
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), 08907 L'Hospitalet de Llobregat, Catalonia, Spain
Author to whom correspondence should be addressed.
Academic Editors: Guido Cavaletti and Valentina Carozzi
Received: 26 April 2015 / Revised: 8 July 2015 / Accepted: 9 July 2015 / Published: 15 July 2015
(This article belongs to the Special Issue Toxicities of Therapeutic Agents Used in Medicine)
Full-Text   |   PDF [575 KB, uploaded 15 July 2015]


Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models. However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice. Consequently, local administration strategies, namely intratympanic administration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin. While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear. This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies. View Full-Text
Keywords: cisplatin; ototoxicity; hearing loss; protective treatment; intratympanic cisplatin; ototoxicity; hearing loss; protective treatment; intratympanic
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Callejo, A.; Sedó-Cabezón, L.; Juan, I.D.; Llorens, J. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies. Toxics 2015, 3, 268-293.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxics EISSN 2305-6304 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top